Ali Nabavizadeh, MD
Associate Professor of Radiology at the Hospital of the University of Pennsylvania
Active Radiologist, Penn Presbyterian Medical Center
Active Radiologist , Pennsylvania Hospital
Attending Radiologist, Hospital of the University of Pennsylvania
Radiologist , Chester County Hospital
Department: Radiology
Contact information
Hospital of the University of Pennsylvania
Department of Radiology
3400 Spruce Street
Philadelphia, PA 19104
Department of Radiology
3400 Spruce Street
Philadelphia, PA 19104
Publications
Education:
MD (School of Medicine)
Shiraz Medical School, 2002.
Permanent linkMD (School of Medicine)
Shiraz Medical School, 2002.
Description of Clinical Expertise
Dr. Nabavizadeh is primarily an adult neuroradiologist with additional training in pediatric neuroradiology and nuclear radiology. He specializes in using neuroimaging to diagnose various diseases of the central nervous system.Description of Research Expertise
Dr. Nabavizadeh is an Associate Professor of Radiology at the Hospital of the University of Pennsylvania with a research appointment at the Children’s Hospital of Philadelphia and the imaging lead of two consortia, CBTN (The Children’s Brain Tumor Network) and PNOC (The Pacific Pediatric Neuro-oncology Consortium) respectively dedicated to biospecimen-driven data generation and precision medicine clinical trials. Dr. Nabavizadeh’s research focuses on multimodality imaging using structural and physiologic MRI imaging with additional PET probes and molecular imaging techniques to better understand the complex nature of brain tumor microenvironment. Dr. Nabavizadeh is the associate editor for the brain tumor section at the American Journal of Neuroradiology and has more than 140 peer-reviewed publications in prestigious journals such as Nature Medicine, Nature Communications, JAMA Neurology, Clinical Cancer Research, Neuro-Oncology, Radiology, and Journal of Nuclear Medicine. He has served as the principal investigator of multiple prospective imaging trials including investigator-initiated trials and industry-sponsored FDA registry trials.Selected Publications
Kazerooni AF, Kraya A, Rathi KS, Kim MC, Kesherwani V, Corbett R, Vossough A, Khalili N, Gandhi D, Familiar NKAM, Jin R, Huang X, Zhu Y, Sickler A, Lueder MR, Phul S, Storm PB, Ware JB, Foster JB, Mueller S, Rokita JL, Fisher MJ, Resnick AC, Nabavizadeh A.: Imaging Clusters of Pediatric Low-Grade Glioma are Associated with Distinct Molecular Characteristics. AJNR Am J Neuroradiol Feb 2025.Kazerooni AF, Kraya A, Rathi KS, Kim MC, Kesherwani V, Corbett R, Vossough A, Khalili N, Gandhi D, Familiar NKAM, Jin R, Huang X, Zhu Y, Sickler A, Lueder MR, Phul S, Storm PB, Ware JB, Foster JB, Mueller S, Rokita JL, Fisher MJ, Resnick AC, Nabavizadeh A.: Imaging Clusters of Pediatric Low-Grade Glioma are Associated with Distinct Molecular Characteristics. AJNR Am J Neuroradiol Feb 2025.
Wills CA, Mohan S, Nabavizadeh A, Patel T, Prior T, Mansour M, McCoy E, Shah S, Angeloni N, O'Neill M, Frangos S, Blessing C, Coghlan L, Maloney E, Wileyto EP, Desai AS, Bagley SJ.: A single-arm phase 2 study of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma. Neurooncol Adv . Jan 2025.
Fathi Kazerooni A, Kraya A, Rathi KS, Kim MC, Vossough A, Khalili N, Familiar AM, Gandhi D, Khalili N, Kesherwani V, Haldar D, Anderson H, Jin R, Mahtabfar A, Bagheri S, Guo Y, Li Q, Huang X, Zhu Y, Sickler A, Lueder MR, Phul S, Koptyra M, Storm PB, Ware JB, Song Y, Davatzikos C, Foster JB, Mueller S, Fisher MJ, Resnick AC, Nabavizadeh A.: Multiparametric MRI Along with Machine Learning Informs on Molecular Underpinnings, Prognosis, and Treatment Response In Pediatric Low-Grade Glioma. Nature Communications Jan 2025.
Mahootiha M, Tak D, Ye Z, Zapaishchykova A, Likitlersuang J, Climent Pardo JC, Boyd A, Vajapeyam S, Chopra R, Prabhu SP, Liu KX, Elhalawani H, Nabavizadeh A, Familiar A, Mueller S, Aerts HJWL, Bandopadhayay P, Ligon KL, Haas-Kogan D, Poussaint TY, Qadir HA, Balasingham I, Kann BH.: Multimodal Deep Learning Improves Recurrence Risk Prediction in Pediatric Low-Grade Gliomas. Neuro Oncol Jan 2025.
Till JE, Seewald NJ, Yazdani Z, Wang Z, Ballinger D, Samberg H, Dandu S, Macia C, Yin M, Abdalla A, Prior T, Shah S, Patel T, McCoy E, Mansour M, Wills CA, Bochenek V, Serrano J, Snuderl M, Phillips RE, O'Rourke DM, Amankulor NM, Nabavizadeh A, Desai AS, Gollomp K, Binder ZA, Zhou W, Bagley SJ, Carpenter EL.: Corticosteroid-dependent association between prognostic peripheral blood cell-free DNA levels and neutrophil-mediated NETosis in patients with glioblastoma. Clin Cancer Res Jan 2025.
Familiar AM, Khalili N, Khalili N, Schuman C, Grove E, Viswanathan K, Seidlitz J, Alexander-Bloch A, Zapaishchykova A, Kann BH, Vossough A, Storm PB, Resnick AC, Kazerooni AF, Nabavizadeh A.: An automated face de-identification AI tool to empower data sharing of pediatric brain MRIs. AJNR Am J Neuroradiol. Nov 2024.
Lost J, Ashraf N, Jekel L, von Reppert M, Tillmanns N, Willms K, Merkaj S, Petersen GC, Avesta A, Ramakrishnan D, Omuro A, Nabavizadeh A, Bakas S, Bousabarah K, Lin M, Aneja S, Sabel M, Aboian M.: Enhancing clinical decision-making: An externally validated machine learning model for predicting isocitrate dehydrogenase mutation in gliomas using radiomics from presurgical magnetic resonance imaging. Neurooncol Adv Oct 2024.
Boyd A, Ye Z, Prabhu S, Tjong MC, Zha Y, Zapaischykova A, Vajapeyam S, Catalano PJ, Hayat H, Chopra R, Liu KX, Nabavizadeh A, Resnick A, Mueller S, Haas-Kogan D, Aerts HJWL, Poussaint T, Kann BH.: Stepwise Transfer Learning for Expert-Level Pediatric Brain Tumor MRI Segmentation in a Limited Data Scenario. Radiol Artif Intell . July 2024.
Maoz SL, Golzar A, Choby G, Hwang PH, Wang EW, Kuan EC, Adappa ND, Geltzeiler M, Getz AE, Humphreys IM, Le CH, Pinheiro-Neto CD, Fischer JL, Chan EP, Abuzeid WM, Chang EH, Jafari A, Kingdom TT, Kohanski MA, Lee JK, Lazor JW, Nabavizadeh A, Nayak JV, Palmer JN, Patel ZM, Resnick AC, Smith TL, Snyderman CH, St John MA, Storm PB, Suh JD, Wang MB, Sim MS, Beswick DM.: University of Washington Quality of Life subdomain outcomes after treatment of sinonasal malignancy: A prospective, multicenter study. Int Forum Allergy Rhinol. June 2024.